Prognostic and clinicopathological significance of PD-L1 in patients with cervical cancer: a meta-analysis

Date 29 September 2019
Event ESMO 2019 Congress
Session Poster Display session 2
Topics Cervical Cancer
Presenter Xiaobin Gu
Citation Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250
Authors X. Gu1, Y. Shi2
  • 1Department Of Radiation Oncology, 1st Affiliated Hospital of Zhengzhou University, 450052 - Zhengzhou/CN
  • 2Department Of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, 450052 - Zhengzhou/CN



Programmed cell death ligand 1 (PD-L1) expression has been shown to associate with poor prognosis in a variety of solid tumors. However, the prognostic value of PD-L1 expression in cervical cancer is still controversial. Therefore, we performed a meta-analysis to investigate the prognostic and clinicopathological impact of PD-L1 in cervical cancer.


A comprehensive literature search was performed in the PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), and Wanfang databases. The correlation between PD-L1 expression and overall survival (OS), progression-free survival (PFS), and clinicopathological features was analyzed by hazard ratios (HR), odds ratios (OR) and corresponding 95% confidence intervals (CI).


Seven studies with 783 patients were included in this meta-analysis. The combined HR and 95%CI of OS was 2.52 (1.09-5.83), p = 0.031. The pooled results for PFS were HR = 2.07, 95%CI=0.52-8.23, p = 0.302. The results of subgroup analysis showed that PD-L1 was a significant prognostic factor of poor OS in Asian patients (HR = 4.77, 95%CI=3.02-7.54, p < 0.001) and of poor PFS in Asian patients (HR = 4.78, 95%CI=1.77-12.91, p = 0.002). However, the pooled results suggested that PD-L1 was not significantly correlated with lymph node metastasis, tumour size, FIGO stage, depth of invasion, lymph-vascular invasion, or age.


The results of this meta-analysis suggest that PD-L1 overexpression is related to poor OS in patients with cervical cancer and poor PFS in Asian patients with cervical cancer. This study also suggests that PD-L1 is a promising prognostic indicator for cervical cancer.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.